09:42 AM EST - Oncolytics Biotech Inc : Reports their second quarter 2023 financial results and operational highlights. Included are; Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression. Pelareorep selected for inclusion in the Precision PromiseSM phase 3 platform trial in pancreatic cancer, designed to accelerate registration path and reduce by ~50% phase 3 costs compared to traditional trial. $24.4 million in cash, cash equivalents and marketable securities as of June 30, 2023 provides projected runway into H2 2024. Strengthened financial position with a successful US$15 million public offering on August 8, 2023. Oncolytics Biotech Inc
shares T.ONC are trading -$0.02 at $2.73.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7034875778838483
